On October 31, the US Food and Drug Administration (FDA) approved pembrolizumab to be used with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer.
For more information read the FDA announcement and Merck announcement.
Posted 11/1/2023
On June 1, 2026, CMS published its interim final rule (IFR), Medicaid Program; Community Engagement Requirement for Certain Individuals in the Federal Register, followed by a public comment period, during which time ACCC submitted a comment letter requesting amendments to the IFR.
